Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SAR405838 (MI 773) 是 MI-773 的类似物,具有抗肿瘤活性。它是一种高效、选择性的MDM2-p53相互作用抑制剂,与 MDM2 结合的Ki 值为 0.88 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 532 | 现货 | ||
2 mg | ¥ 768 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,980 | 现货 | ||
25 mg | ¥ 3,590 | 现货 | ||
50 mg | ¥ 5,190 | 现货 | ||
100 mg | ¥ 7,330 | 现货 | ||
500 mg | ¥ 14,600 | 现货 |
产品描述 | MI-773 (SAR405838 (MI 773)) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
靶点活性 | MDM2:0.88 nM(Ki) |
体外活性 | MI-773 binds to MDM2 with Ki of 0.88 nM. MI-773 potently inhibits cell growth in cancer cell lines, including SJSA-1 (IC50, 0.092 μM), RS4;11 (IC50, 0.089 μM), LNCaP (IC50, 0.27 μM), and HCT-116 (IC50, 0.20 μM) cells, and displays high selectivity over cancer cell lines with mutated or deleted p53, including SAOS-2 (IC50, >10 μM), PC-3 (IC50, >10 μM), SW620 (IC50, >10 μM), and HCT-116 (p53-/-) (IC50, >20 μM) cells. [1] |
体内活性 | In the SJSA-1 osteosarcoma, acute lymphoblastic leukemia RS4;11, LNCaP prostate cancer, and HCT-116 colon cancer xenograft model, MI-773 (p.o.) effectively inhibits tumor growth in a dose-dependent manner (10 mg/kg, 30 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg,). [1] |
激酶实验 | Fluorescence-polarization binding assay: Binding af?nities of MDM2 inhibitors and p53 peptide to MDM2 protein are determined using an Fluorescence-polarization (FP) binding assay. Binding af?nities of MI-773 to Bcl-2, Bcl-xL, Mcl-1, and β-catenin are determined using a competitive FP-based assay, and its binding af?nity to MDMx is determined using Biolayer Interferometry technology. |
细胞实验 | Cell growth inhibition activity is determined in a water-soluble tetrazolium-based assay. Cell death is measured by trypan blue staining and apoptosis is determined using an Annexin V-FLUOS staining kit.(Only for Reference) |
别名 | MI773, MI 773, MI-77301, MI-773 |
分子量 | 562.5 |
分子式 | C29H34Cl2FN3O3 |
CAS No. | 1303607-60-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (165.3 mM)
Ethanol: 29 mg/mL (51.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.7778 mL | 8.8889 mL | 17.7778 mL | 44.4444 mL |
5 mM | 0.3556 mL | 1.7778 mL | 3.5556 mL | 8.8889 mL | |
10 mM | 0.1778 mL | 0.8889 mL | 1.7778 mL | 4.4444 mL | |
20 mM | 0.0889 mL | 0.4444 mL | 0.8889 mL | 2.2222 mL | |
50 mM | 0.0356 mL | 0.1778 mL | 0.3556 mL | 0.8889 mL | |
DMSO | 100 mM | 0.0178 mL | 0.0889 mL | 0.1778 mL | 0.4444 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SAR405838 1303607-60-4 Apoptosis Ubiquitination Mdm2 E1/E2/E3 Enzyme MDM-2/p53 SAR 405838 Ubiquitin activating enzyme MI77301 inhibit MI773 Ubiquitin ligase Inhibitor MI 77301 MI 773 MI-77301 Ubiquitin conjugating enzyme E2 conjugating enzyme SAR-405838 E3 ligating enzyme E1 activating enzyme MI-773 inhibitor